Resmed Inc [RMD] stock is trading at $259.51, up 1.90%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RMD shares have gain 4.55% over the last week, with a monthly amount glided 2.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Resmed Inc [NYSE: RMD] stock has seen the most recent analyst activity on December 16, 2025, when Robert W. Baird downgraded its rating to a Neutral but kept the price target unchanged to $275 for it. Previously, Citigroup started tracking the stock with Buy rating on September 18, 2025, and set its price target to $330. On September 02, 2025, upgrade upgraded it’s rating to Outperform. RBC Capital Mkts upgraded its rating to an Outtperform but stick to its price target of $294 on July 15, 2025. Morgan Stanley initiated its recommendation with an Overweight and recommended $280 as its price target on March 19, 2025. In a note dated January 16, 2025, Goldman initiated a Buy rating.
Resmed Inc [RMD] stock has fluctuated between $199.92 and $293.81 over the past year. Currently, Wall Street analysts expect the stock to reach $294 within the next 12 months. Resmed Inc [NYSE: RMD] shares were valued at $259.51 at the most recent close of the market. An investor can expect a potential return of 13.29% based on the average RMD price forecast.
Analyzing the RMD fundamentals
Resmed Inc [NYSE:RMD] reported sales of 5.26B for the trailing twelve months, which represents a growth of 9.07%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.33%, and Net Profit Margin reading is 0.27%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.25 and Total Capital is 0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Resmed Inc’s Current Ratio is 2.89. Also, the Quick Ratio is 2.13, while the Cash Ratio stands at 1.1. Considering the valuation of this stock, the price to sales ratio is 7.21, the price to book ratio is 6.19 and price to earnings (TTM) ratio is 26.56.
Transactions by insiders
Recent insider trading involved FARRELL PETER C, Director, that happened on Jan 07 ’26 when 2000.0 shares were sold. Chairman and CEO, Farrell Michael J. completed a deal on Jan 07 ’26 to sell 4991.0 shares. Meanwhile, Director Peter C Farrell bought 2000.0 shares on Jan 07 ’26.
